The University of Tokyo

Modalis Therapeutics Corporation

Keith M Connolly

Osamu Nureki

Hiroshi Nishimasu

Yuanbo Qin

Tetsuya Yamagata

Iain Robert Thompson

Hisato Hirano

Shohei Kajimoto

A mutant SaCas9 protein such as a protein having an amino acid sequence resulting from mutations of glutamic acid at the 782-position to lysine (E782K), leucine at the 800-position to arginine (L800R), asparagine at the 968-position to arginine (N968R), asparagine at the 985-position to alanine (N985A), arginine at the 991-position to alanine (R991A), alanine at the 1021-position to serine (A1021S), threonine at the 927-position to lysine (T927K), lysine at the 929-position to asparagine (K929N), and isoleucine at the 1017-position to phenylalanine (I1017F) in SEQ ID NO: 2 has relaxed restriction on target sequence while maintaining binding ability to guide RNA, and is useful as a tool for gene editing.

Modified CAS9 protein, and use thereof

Growing community of inventors

Cambridge, MA, United States of America

Keith M Connolly